A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
Trial details
- Registry ID
- NCT05966493
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as NEXAGON®
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCEDNCT05966493 | Glaukos Corporation | Phase 2 | Recruiting | 2025-12Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |